title: Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.
authors.forename: Johan
authors.initials: J
authors.lastname: Westin
authors.forename: Kristoffer
authors.initials: K
authors.lastname: Hellstrand
authors.forename: Asa
authors.initials: A
authors.lastname: Alsiö
authors.forename: Magdalena
authors.initials: M
authors.lastname: Ydreborg
authors.forename: Carlo
authors.initials: C
authors.lastname: Ferrari
authors.forename: Avidan U
authors.initials: AU
authors.lastname: Neumann
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Pawlotsky
authors.forename: Solko W
authors.initials: SW
authors.lastname: Schalm
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Elke
authors.initials: E
authors.lastname: Verhey-Hart
authors.forename: Martin
authors.initials: M
authors.lastname: Lagging
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a